-
The PLUS KRAS G12C inhibitor completes the first patient administration of the STK11 co-mutant IIa trial
Time of Update: 2022-09-14
Dr. Yinxiang Wang, Chairman and CEO of Jiacosi, said: "JAB-21822 is the first and only drug in China that has been approved clinically for the first-line treatment of STK11 and KRAS G12C co-mutant non-small cell lung cancer.
-
Laikai Pharmaceuticals LAE201INT2101 Clinical Phase I/II study completed the first subject administration in Korea
Time of Update: 2022-09-14
LAE201INT2101 is a multicenter, open-label Phase I/II clinical study evaluating the safety and antitumor efficacy of LAE001+LAE002 (afuresertib) as a combination therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) who have advanced or intolerated disease after standard treatment.
-
Invest $2.2 million! The pharmaceutical company will be in Singapore for another city
Time of Update: 2022-09-14
Publicly available, Catalent is a company dedicated to delivering technology, development and manufacturing solutions for pharmaceuticals, biologics, cell and gene therapies, and consumer health products, with four divisions, including SoftGel and Oral Technologies, Biologics, Oral and Specialist Delivery, and Clinical Supply Services.
-
Suvotinib treatment of EGFR exon20ins NSCLC China Registered Clinical Attainment Primary Endpoint
Time of Update: 2022-09-14
" The 2022 Annual Meeting of the European Society of Oncology (ESMO) announced that suvotinib reached the primary endpoint of WU-KONG6 in patients with advanced non-small cell lung cancer (NSCLC) who had previously received platinum-based chemotherapy and carried EGFR exon20ins, with encouraging clinical results.
-
2022 ESMO:DZD1516 International Multicenter Breast Cancer Clinical Study Results Positive
Time of Update: 2022-09-14
Based on the unique tumor central nervous system metastasis research platform, Di Zhe designed and developed DZD1516, a highly selective HER2 inhibitor with the ability to fully penetrate the blood-brain barrier.
-
NANOBIOTIX and Liantuo Biotech announced that the NANOAY-312 Phase III trial evaluating NBTXR3 for the treatment of head and neck cancer has completed the first patient recruitment in Asia
Time of Update: 2022-09-14
For nanobiotix's critical Phase III trial for the treatment of head and neck cancer, its regional start-up work is proceeding as planned, and Liantuo completes the first patient recruitment in Asia T
-
Connaeus Biopharma successfully completed a Phase I single dose escalation trial of CBP-174
Time of Update: 2022-09-14
"This positive data from the first human clinical trial shows that CBP-174 is making good progress as a new treatment for pruritus associated with allergic and inflammatory skin diseases, including atopic dermatitis, which plague millions of people worldwide," said Dr. Wei Zheng, co-founder and CEO of Connad, "This is the first clinical trial of Connad's third-phase clinical phase drug candidate.
-
Data from the obutinib combined with RCHOP treatment with primary extranodal initial treatment non-GCB subtype DLBCL were selected for the 2022 ESMO Oral Report
Time of Update: 2022-09-14
From September 9 to 13, 2022, the 2022 European Society of Oncology (ESMO) Annual Conference will be held in the form of an online + offline combination at the Porte de Versailles exhibition hall in
-
Skin immune biomarker testing can help predict eczema in infants
Time of Update: 2022-09-14
Dr Anne-Sofie Halling, lead author and co-researcher of the study from the University of Copenhagen Bispebjerg Hospital, commented: "To our knowledge, this is the first time that noninvasive collection of skin biomarkers can be used to predict the subsequent onset and severity of pediatric-specific eczema.
-
New ideas for prostate cancer treatment: lowering androgen receptors with PROTAC!
Time of Update: 2022-09-09
Recently, GeninTech, a subsidiary of pharmaceutical giant Roche, and Jiyu Small Molecule Innovation Research Institute, a subsidiary of Jimin Trust, signed an exclusive licensing agreement to buy a prostate cancer targeted androgen receptor (AR) protein degradation (TPD) drug for up to $650 million: "JMKX002992".
-
Keixing Announces the Completion of the First Patient Enrollment in the Chinese Cohort of the Phase 3 aficamten Clinical Trial
Time of Update: 2022-09-08
"Hypertrophic cardiomyopathy is a common hereditary cardiovascular disease, and the existing drug therapy is recommended on the basis of empirical treatment, not targeting the underlying pathological mechanism of HCM, namely excessive myocardial contraction .
-
Sirnaomics Advances GalAhead(TM) Delivery Platform-Based RNAi Therapies for Complement-Mediated-Related Diseases
Time of Update: 2022-09-08
Sirnaomics announced that the company is actively advancing its GalAhead™ RNAi delivery platform in a pipeline of novel therapeutics focused on the treatment of complement-mediated diseases .
-
Ou Tangjing(R) (Embagliflozin Tablets) became the first and currently the only SGLT-2 inhibitor approved in China for the treatment of adult patients with symptomatic chronic heart failure (regardless of the patient's ejection fraction).
Time of Update: 2022-09-07
As the world's first and only research-proven SGLT-2 inhibitor for heart failure with total ejection fraction, we believe that Ou Tangjing® will be the first in China Heart failure patients provide new treatment options .
-
AstraZeneca China's first rare disease drug Sulirui achieved milestone progress in China, providing new options for rare disease treatment
Time of Update: 2022-09-07
As a prescription drug approved in China for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) in adults and children [1], this change of approval marks Eculizumab.
-
Longli Aviation Technology undertakes the business of AVIC Manufacturing Institute, and accelerates the process of domestic substitution of wet hybrid granulation line and high-efficiency coating machine
Time of Update: 2022-09-06
According to the data, the main business of Longli Aviation Technology is the research and development, production, sales and service of high-efficiency coating machines and wet granulation lines, providing customers with overall solutions for solid dosage.
-
Novartis' spin-off of the generic drug business has made new progress and will be completed in the second half of 2023
Time of Update: 2022-09-06
Novartis announced plans to divest its generic and biosimilar division Sandoz as a newly listed independent operating company with plans to complete the spin-off process in the second half of 2023.
-
Berinko and Schooler Allibert are working together to help develop China's biopharmaceutical industry
Time of Update: 2022-09-06
On August 26, in response to the foreseeable market demand for China's biopharmaceutical hydration products, Bio-Link, a supplier of core equipment and consumables solutions for biological processes in China, and Schoeller Allibert, a company in the field of logistics packaging in the European market, held a strategic cooperation signing ceremony in Suzhou, and the two sides will jointly create a diagonal transfer box for the localization of 2D reservoir bags.
-
The vice president of this pharmaceutical company has been replaced! The company's net profit in the first half of the year increased by 20% year-on-year
Time of Update: 2022-09-06
According to the 2022 semi-annual report, tusS Pharmaceutical's operating income in the first half of the year was about 178 million yuan, an increase of 20.
According to the 2022 semi-annual report, tusS Pharmaceutical's operating income in the first half of the year was about 178 million yuan, an increase of 20.
-
Nestlé Shengming Garden (Garden of Life) to force the Chinese market to launch the first domestic new products yisheng
Time of Update: 2022-09-06
Recently, Garden of Life, a high-end nutritional dietary supplement brand affiliated with Nestlé's health science business, held an online new product launch and launched two new products: the "green
-
The pharmaceutical company expects that 3 blockbuster drugs will be approved before the end of the year, and will enter the market for 100 billion yuan!
Time of Update: 2022-08-30
Up to now, the company has a total of 86 pharmaceutical research projects, including 43 innovative drugs and biological drug projects; in addition, canagliflozin tablets, liraglutide injection, and sorafenib tosylate tablets are three major The pound products are expected to be approved before the end of the year, and they will enter the market of 100 billion yuan .
